News
-
-
PRESS RELEASE
BioNxt Accelerates ODF for Multiple Sclerosis Toward Human Clinical Study with >40% Bioavailability Improvement and Myasthenia Gravis Expansion
BioNxt announces progress in cladribine oral thin film development, with focus on bioavailability improvement and human clinical study for Multiple Sclerosis. Expansion into Myasthenia Gravis also planned -
-
-
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Aroundtown SA resolves on Share Buy-Back Programme with a volume of up to 250 million Euro
Aroundtown SA resolves on Share Buy-Back Programme with a volume of up to 250 million Euro. The Board of Directors approved the buyback of a maximum of 120 million shares by December 31, 2026